Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.
Cong Dai,Meng Wang,Jun Lu,Zhiming Dai,Shuai Lin,Pengtao Yang,Tian Tian,Xinghan Liu,Weili Min,Zhijun Dai
DOI: https://doi.org/10.2147/OTT.S138044
IF: 4
2017-01-01
OncoTargets and Therapy
Abstract:Background: PD-L1 has been reported to be expressed in diverse human malignancies. However, the prognostic value of PD-L1 in digestive system cancers remains inconclusive. Therefore, we conducted this meta-analysis to evaluate the prognostic impact of PD-L1 expression in digestive system cancers. Materials and methods: We searched the PubMed, Embase, and the Chinese National Knowledge Infrastructure for publications concerning PD-L1 expression in digestive system cancers. Correlations of PD-L1 expression level with overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) were analyzed. Results: Finally, 32 studies with 7,308 patients were included. Our results show that PD-L1 expression was significantly associated with poorer OS (hazard ratio [HR] = 1.44, 95% confidence interval [CI] = 1.18-1.76, P<0.001), but not DFS (HR = 0.91, 95% CI = 0.61-1.37, P=0.657) or RFS (HR = 1.27, 95% CI = 0.75-2.14, P=0.368). Moreover, in the subgroup analysis, significant associations between PD-L1 expression and OS were found in Asians (HR = 1.50, 95% CI = 1.19-1.89, P=0.001), gastric cancer (HR = 1.43, 95% CI = 1.05-1.94, P=0.021), and pancreatic carcinoma (HR = 2.64, 95% CI = 1.78-3.93, P<0.001). Conclusion: These results suggest that the expression of PD-L1 is associated with worse OS in digestive system cancers, especially in gastric cancer and pancreatic cancer. In addition, PD-L1 may act as a new parameter for predicting poor prognosis and a promising target for anticancer therapy in digestive system cancers.